Markets:

Overview

News

Currencies

International

Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

431.91 +9.59 (+2.27%)

Streaming Delayed Price Updated: 10:25 AM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

68 69 Next >

These 3 Stocks Have Beaten the S&P Average Return for Years and Are Likely to Continue That Trend ↗

January 10, 2024

These winners seem likely to keep up their winning ways.

Via The Motley Fool

Topics Stocks

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 16 Analysts ↗

January 09, 2024

Via Benzinga

Vertex Announces Approval of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™, for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT) in Kingdom of Saudi Arabia

January 09, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

A Look Into Vertex Pharmaceuticals Inc's Price Over Earnings ↗

January 09, 2024

Via Benzinga

$1000 Invested In This Stock 15 Years Ago Would Be Worth $14,000 Today ↗

January 08, 2024

Via Benzinga

Is Vertex Pharmaceuticals Stock a Buy Now? ↗

January 06, 2024

The biotech's prospects keep improving.

Via The Motley Fool

Decoding Vertex Pharmaceuticals's Options Activity: What's the Big Picture? ↗

December 27, 2023

Via Benzinga

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow ↗

December 27, 2023

With a new medicine on the market and plenty of money, Vertex is in great shape.

Via The Motley Fool

2 low-priced gene therapy stocks to speculate on

January 08, 2024

Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe

Via MarketBeat

5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday ↗

January 08, 2024

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting.

Via Benzinga

The Ultimate Growth Stock to Buy With $1,000 Right Now ↗

January 08, 2024

The stock, trading for about $60, has plenty of room to run.

Via The Motley Fool

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 07, 2024

From Vertex Pharmaceuticals Incorporated

Via Business Wire

5 Top Stocks to Buy in January ↗

January 07, 2024

Start the year off right by investing in these quality businesses.

Via The Motley Fool

Investing Trends to Follow in 2024 ↗

January 06, 2024

We've also got Motley Fool co-founder Tom Gardner sharing an investing lesson from last year and a stock for this one.

Via The Motley Fool

Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗

January 05, 2024

Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.

Via Investor's Business Daily

2 Biotech Stocks With Huge Catalysts in 2024 ↗

January 05, 2024

Important clinical-trial readouts on the way could send these stocks soaring in early 2024.

Via The Motley Fool

Gen Z’s Top Picks for 2024: 7 Trending Stocks Among Young Investors ↗

January 04, 2024

Gen Z stocks include companies the generation prefers to invest in while capturing the emerging economic force they represent.

Via InvestorPlace

Will the Biotech sector sustain its momentum in 2024?

January 04, 2024

The iShares Biotechnology ETF (NASDAQ: IBB) emerged as a standout star, closing the first day of the year with a solid upswing of nearly 4%.

Via MarketBeat

Topics ETFs

The Best Stocks to Invest $1,000 in Right Now ↗

January 04, 2024

It's not too late to get in on these market beaters.

Via The Motley Fool

Here's Why 2024 Could Be a Big Year for CRISPR Therapeutics ↗

January 04, 2024

CRISPR Therapeutics' shares climbed considerably last year -- but more gains could be just ahead.

Via The Motley Fool

3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition ↗

January 03, 2024

Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside.

Via InvestorPlace

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) Climbs to New 52-Week High

January 03, 2024

Via Investor Brand Network

January Has Been 1 of the Worst Months for the S&P 500 Over the Last 20 Years. Here Are 3 Stocks to Buy Anyway. ↗

January 03, 2024

These stocks are smart picks to buy now, regardless of whether the S&P 500 stocks start off 2024 poorly.

Via The Motley Fool

Topics Stocks

3 Biotech Stocks Set for Breakthroughs in 2024 ↗

January 02, 2024

With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks.

Via InvestorPlace

2 gene-editing stocks reshaping hereditary disease treatments

January 02, 2024

Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal

Via MarketBeat

Prediction: These 3 Stocks Will Soar in 2024 ↗

January 01, 2024

Investors could enjoy an especially happy new year with these great stocks.

Via The Motley Fool

1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024 ↗

December 31, 2023

Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name.

Via The Motley Fool

Want $1 Million in Retirement? Invest $300,000 in These 3 Stocks and Wait a Decade. ↗

December 30, 2023

These stocks offer attractive risk-reward profiles.

Via The Motley Fool

2 Exceptional Growth Stocks Up 42% and 66% to Buy Right Now ↗

December 29, 2023

It's been a crazy year across sectors, but winners remain.

Via The Motley Fool

CRISPR Therapeutics sets sights on gene-editing cures for disease

December 27, 2023

On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for

Via MarketBeat

< Previous 1 2

...

25 26 27 28 29 30 31 32 33

...

68 69 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.